November 2023 FDA Recall Trospium Chloride by Padagis Us Llc
D-0139-2024 - Failed Tablets/Capsules specifications; missing/broken/extra tablets within the capsules

This Class II drug recall was voluntarily initiated by Padagis Us Llc on November 1, 2023 for the product Trospium Chloride. The FDA reported the reason for recall as failed tablets/capsules specifications; missing/broken/extra tablets within the capsules. The product was distributed Nationwide and the recall is currently ongoing.

Recall Number: D-0139-2024

Reason for Recall
Failed Tablets/Capsules specifications; missing/broken/extra tablets within the capsules
Initiated
11-01-2023
Reported
12-13-2023
Quantity
7,032 bottles

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Nationwide in the USA
Trospium Chloride Extended-Release Capsules, 60 mg, 30 Capsules per bottle, Rx Only, Manufactured By: Sidmak Laboratories (India) Pvt. Ltd. Plot No. 20, Pharmacity, Selaqui Industrial Area, Dehradun-248 197 Uttarakhand, India Distributed By: Padagis, Allegan, MI 49010. NDC: 0574-0118-30

Batch or Lot Expiration Information

Lot# Lot: 231104, 231105, 231106, exp 7/31/2025

Affected Packages Involved in this Recall